Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Nov 27, 2020 9:20am
83 Views
Post# 31987924

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:While other biotech steam forward. DUG looks behind the

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:While other biotech steam forward. DUG looks behind the Not that simple to buy more after almost seven Years of limbo and decline. GUD on a balance sheet approached it is a no brainer but betting on MNGT again ..and again is a nightmare. How many times can they get it wrong? How long can they sit on the cash and do nothing? If they do not resign will they add more fire power to MNGT? Or will they remain in hibernation forever? You cannot keep expecting MNGT to change when they keep doing the same thing and expect investors and the market to reward then with higher share price. Because of GUD I have done very well with PRN and I am deep with ATE. In the last six months I have beaten the market by far mostly US tech and biotech, amazon. The only dog GUD. 4% of the portfolio.  In Late March with their cash there were huge opportunities for GUD but they were at sleep as usual. GUD has lost investor's faith. Even if the share price goes back to $10 the original investors will not keep up with market index. In the next five Years GUD would have to go to $15 or more to keep up with market index.  Not only we lost capital by staying with GUD but we also lost opportunity cost of not investing in winners/profits.  I guess if you are GT and entering into GUD now the down site is low but he too may wait Years a d piss ing in the wind like most of us long  
Bullboard Posts